Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LupinNSE:LUPIN -0.72%92 Days Payable is 97.02 as of Jun. 2026, which is 34% below its 10-year median of 146.96. GuruFocus rates NSE:LUPIN with a GF Score™ of 92/100 and a GF Value™ of ₹2,592.77 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 928 Drug Manufacturers companies, Lupin ranks better than 79.85% on this metric.
Lupin's average Accounts Payable for the
three
months ended in Jun. 2026 was ₹41,731 Mil. Lupin's Cost of Goods Sold for the
three
months ended in Jun. 2026 was ₹39,251 Mil.
Hence, Lupin's Days Payable for the
three
months ended in Jun. 2026 was 97.02.
The historical rank and industry rank for Lupin's Days Payable or its related term are showing as below:
NSE:LUPIN'
s Days Payable Range Over the Past 10 Years
Min: 110.65 Med: 146.96 Max: 171.78
Current: 167.74
During the past 13 years, Lupin's highest Days Payable was 171.78. The lowest was 110.65. And the median was 146.96.
NSE:LUPIN's Days Payable is ranked better than 79.85% of 928
companies
in the Drug Manufacturers industry
Industry Median: 88.385
vs NSE:LUPIN: 167.74
Lupin's Days Payable
increased
from Jun. 2025 (85.59) to Jun. 2026 (97.02).
It may suggest that Lupindelayed paying its suppliers.
The historical data trend for Lupin's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Lupin's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lupin Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lupin's Days Payable distribution charts can be found below:
* The bar in red indicates where Lupin's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Lupin's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lupin (NSE:LUPIN) has a Days Payable of 97.02 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Lupin and its competitors. This is 34% below median its historical median of 146.96. Over the past decade, Lupin's Days Payable has ranged from 110.65 to 171.78. According to the industry distribution chart, Lupin ranks #187 out of 928 companies in the Drug Manufacturers industry, placing it in the top 20.2%.
Is Lupin's Days Payable too high?
Lupin's current Days Payable of 97.02 is 34% below median its 10-year median of 146.96. Over the past 10 years, this metric has ranged from a low of 110.65 to a high of 171.78. The Drug Manufacturers industry median Days Payable is 88.39. Lupin's value of 97.02 is 9.8% above this industry median. Based on the distribution chart, Lupin ranks #187 out of 928 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Lupin has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lupin's Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Lupin ranks #187 out of 928 companies for Days Payable. This places Lupin in the top 20% of its industry — outperforming the majority of peers. The industry median Days Payable is 88.39. Lupin's value of 97.02 is 9.8% above this benchmark. Historically, Lupin's own Days Payable has ranged from 110.65 to 171.78 over the past decade. While the company's 10-year median is 146.96 vs. the industry median of 88.39, Lupin has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 88.39, based on 928 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lupin's current Days Payable of 97.02 is 9.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Lupin and its competitors. For the Drug Manufacturers industry, the median Days Payable is 88.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lupin's current Days Payable is 97.02, which is 34% below median its own 10-year median of 146.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lupin stock overvalued right now?
Based on GuruFocus' analysis, Lupin (NSE:LUPIN) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹2,592.77, compared to a current price of ₹2,083.00 — trading 19.7% below its estimated fair value. The current Days Payable is 97.02, which is 34% below median its 10-year median of 146.96 and 9.8% above the Drug Manufacturers industry median of 88.39. Lupin's overall GF Score™ is 92/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Lupin (NSE:LUPIN), the current Days Payable is 97.02 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lupin (NSE:LUPIN) Overvalued in 2026?
Based on GuruFocus' analysis, Lupin stock appears to be undervalued.
The current stock price of ₹2,083.00 is trading 19.7% below its estimated GF Value™ of ₹2,592.77.
GuruFocus considers Lupin to be Modestly Undervalued.
Key valuation signals for NSE:LUPIN:
Days Payable: 97.02 (34% below median its 10-year median of 146.96)
GF Value™: ₹2,592.77 vs. price of ₹2,083.00 (19.7% below fair value)
Industry Position: 9.8% above the Drug Manufacturers median (#187 of 928)
No single metric tells the full story. See the NSE:LUPIN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lupin Ltd is a specialty and generic drug manufacturing company. The company produces, develops, and markets branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) globally. It has a presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, Central Nervous System, GastroIntestinal, and other drug therapy segments. The operations of the company are limited to the segments, namely pharmaceuticals which derives key revenue, and others. It also maintains a pipeline in high-barrier markets such as Inhalation, Biosimilars, and Complex Injectables. The vast majority of the company's sales are generated in the United States, followed by India, and other countries.
92GF Score
Get the complete analysis for NSE:LUPIN
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:LUPIN has been successfully added to your 
